Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

Stock Information for InMed Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InMed Pharmaceuticals Inc.

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.